Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

days after the end of therapy. The primary endpoint will be the clinical cure rate at the TOC visit.

Progress of Phase I programme with oral iclaprim

The completed Phase I study was designed as a double-blind, placebo-controlled, dose escalation trial. A total of 32 subjects participated in the study (16 males and 16 females). Safety and tolerability were evaluated after administration of supra-therapeutic doses aimed at determining the maximal tolerated dose.

No serious adverse events were reported. Only after administering five-fold the targeted therapeutic dose, the number of adverse events showed a significant increase relative to placebo and this dose was then defined as the maximal tolerated dose in humans. All reported adverse events were mild-to-moderate in nature and mainly concerned vomiting and nausea. As in previous clinical trials with iclaprim, ECG monitoring was conducted. No clinically relevant increases in the QTc interval were observed at any of the investigated doses.

A further Phase I study, investigating the safety and tolerability of multiple administration of supra-therapeutic doses of oral iclaprim is currently ongoing. In addition, slow-release administration at supra-therapeutic doses is being investigated.

"Rolling" NDA for intravenous iclaprim in cSSSI; electronic submission of first modules due before year-end 2007

Arpida has made very good progress in compiling the New Drug Application (NDA) for intravenous iclaprim in its first indication, complicated Skin and Skin Structure Infections (cSSSI). The NDA forms the basis for the U.S. Food and Drug Administration (FDA) for its evaluation of a drug candidate's eligibility for marketing approval.

Arpida has agreed with the U.S. FDA to file the NDA in a rolling process. Using a 'rolling NDA' allows the different modules within the overall package to be filed individually. Arpida has further agreed to file the NDA in an electronic format. Test
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... DIEGO and TORONTO , ... TSX: APS), a clinical-stage company developing new therapeutics and ... today announced that William G. Rice , Ph.D., ... the upcoming 27th Annual ROTH Conference on Tuesday, March ... The Ritz Carlton, Laguna Niguel, CA. ...
(Date:3/5/2015)... The next implants made from the ... mark (European) approval. The CE mark is necessary for ... and the European Union. Following the Class IIb approval ... implants supplied by the Turkey-based company Osimplant for the ... Cervical Expandable Bladed HA PEEK Cage line of spinal ...
(Date:3/4/2015)... , March 4, 2015  Brooklyn residents now have ... and chronic pain and injuries. Nunzio Saulle , ... grand opening of his NJS Physical Medicine and Rehabilitation ... on Thursday, March 5, 2015. Health Plus Management, LLC ... is located at 1178 Flatbush Avenue. This new PM&R ...
(Date:3/4/2015)... 2015 PRC Clinical, a ... Francisco Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, ... with Israeli life science companies seeking to conduct U.S. ... services span all phases of human trials, from Phase ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4
... , Point-of-Care Diagnostics Initiative is part of ... & Melinda Gates Foundation and Grand Challenges Canada , ... to create a low-cost portable testing platform for molecular diagnostics ... expected to be completed by 2014, enabling rapid integration of ...
... Corp. Ltd., a developer and marketer of innovative products ... today announced it has entered into a non-exclusive agreement ... RNA extraction products in Sweden and other selected countries ... real-time PCR (qPCR) services and products.  This new agreement ...
... RICHMOND, Calif., May 2, 2012 Sangamo BioSciences, Inc. (Nasdaq: ... accomplishments. For the first quarter ended March 31, ... $0.14 per share, compared to a net loss of $9.6 million, ... of March 31, 2012, the company had cash, cash equivalents and ...
Cached Biology Technology:QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 2QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 3QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 4QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 5ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 2ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 3Sangamo BioSciences Reports First Quarter 2012 Financial Results 2Sangamo BioSciences Reports First Quarter 2012 Financial Results 3Sangamo BioSciences Reports First Quarter 2012 Financial Results 4Sangamo BioSciences Reports First Quarter 2012 Financial Results 5Sangamo BioSciences Reports First Quarter 2012 Financial Results 6Sangamo BioSciences Reports First Quarter 2012 Financial Results 7
(Date:3/2/2015)... 2, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new implementation of ... enable rapid and secure transactions and reliable identification ... is a turnkey solution providing mouse and keyboard ... integrate fingerprint ID solutions into their product offerings, ...
(Date:2/25/2015)... Ark. , Feb. 25, 2015  ABC ... and billing in the Health and Fitness Industry, ... well as to MYiCLUBonline.  The latest upgrade includes ... the inclusion of cardless check-in via Identity One ... the first time through interactive displays at the ...
(Date:2/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ... "Global 2D Gesture Recognition Market 2015-2019" report ... forecast the Global 2D Gesture Recognition market to ... period 2014-2019 The increased demand for ... of the major trends in the market. The ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2
... the body of a dead jay, according to new research ... can last for up to half an hour. Anecdotal ... birds in the crow family, react to dead of their ... carried out the work. But few experimental studies have explored ...
... A bill concerning the introduction of biometric ... country,s parliament. Biometric documents will contribute to border security ... for the creation of a unified state demographic register, ... Additionally, the draft stipulates issuing the documents for traveling ...
... more than half a millimetre in length and lives on ... first time in Europe. The finding suggests that it arrived ... 30 years ago but it is still unknown whether it ... damages the expansion of the already established red swamp crayfish., ...
Cached Biology News:Scrub jays react to their dead 2Ukraine to Introduce European Standard of Biometric ID 2A minute crustacean invades the red swamp crayfish 2
... 45° Fixed Angle Rotor ... Centra CL2, Centra CL3CL3R, and ... concentration of sputum samples and ... samples. Provides individual aerosol containment. ...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
Buckets for tube holder inserts...
Rotor for four tube-loaded buckets; ma RCF 2550g; sold without buckets...
Biology Products: